167 related articles for article (PubMed ID: 36097320)
21. Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose.
Bergmann TK; Hennig S; Barraclough KA; Isbel NM; Staatz CE
Ther Drug Monit; 2014 Feb; 36(1):62-70. PubMed ID: 24089074
[TBL] [Abstract][Full Text] [Related]
22. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
[TBL] [Abstract][Full Text] [Related]
23. Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation.
Han N; Ha S; Yun HY; Kim MG; Min SI; Ha J; Lee JI; Oh JM; Kim IW
Basic Clin Pharmacol Toxicol; 2014 May; 114(5):400-6. PubMed ID: 24238261
[TBL] [Abstract][Full Text] [Related]
24. Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients.
Cai X; Song H; Jiao Z; Yang H; Zhu M; Wang C; Wei D; Shi L; Wu B; Chen J
Eur J Pharm Sci; 2020 Sep; 152():105448. PubMed ID: 32621968
[TBL] [Abstract][Full Text] [Related]
25. Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.
Buendia JA; Bramuglia G; Staatz CE
Ther Drug Monit; 2014 Aug; 36(4):442-7. PubMed ID: 24378577
[TBL] [Abstract][Full Text] [Related]
26. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation.
Staatz CE; Willis C; Taylor PJ; Lynch SV; Tett SE
Liver Transpl; 2003 Feb; 9(2):130-7. PubMed ID: 12548506
[TBL] [Abstract][Full Text] [Related]
27. Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients.
Lee JY; Hahn HJ; Son IJ; Suh KS; Yi NJ; Oh JM; Shin WG
Pharmacotherapy; 2006 Aug; 26(8):1069-77. PubMed ID: 16863483
[TBL] [Abstract][Full Text] [Related]
28. Evaluating tacrolimus pharmacokinetic models in adult renal transplant recipients with different CYP3A5 genotypes.
Hu C; Yin WJ; Li DY; Ding JJ; Zhou LY; Wang JL; Ma RR; Liu K; Zhou G; Zuo XC
Eur J Clin Pharmacol; 2018 Nov; 74(11):1437-1447. PubMed ID: 30019212
[TBL] [Abstract][Full Text] [Related]
29. Prediction of the tacrolimus population pharmacokinetic parameters according to CYP3A5 genotype and clinical factors using NONMEM in adult kidney transplant recipients.
Han N; Yun HY; Hong JY; Kim IW; Ji E; Hong SH; Kim YS; Ha J; Shin WG; Oh JM
Eur J Clin Pharmacol; 2013 Jan; 69(1):53-63. PubMed ID: 22660440
[TBL] [Abstract][Full Text] [Related]
30. Dosage optimization of tacrolimus based on the glucocorticoid dose and pharmacogenetics in adult patients with systemic lupus erythematosus.
Wang CB; Zhang YJ; Zhao MM; Zhao L
Int Immunopharmacol; 2023 Nov; 124(Pt A):110866. PubMed ID: 37678026
[TBL] [Abstract][Full Text] [Related]
31. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
32. CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.
Dong Y; Xu Q; Li R; Tao Y; Zhang Q; Li J; Ma Z; Shen C; Zhong M; Wang Z; Qiu X
Gene; 2022 Jan; 809():146007. PubMed ID: 34688813
[TBL] [Abstract][Full Text] [Related]
33. Prediction of tacrolimus dosage in the early period after heart transplantation: a population pharmacokinetic approach.
Han Y; Zhou H; Cai J; Huang J; Zhang J; Shi SJ; Liu YN; Zhang Y
Pharmacogenomics; 2019 Jan; 20(1):21-35. PubMed ID: 30730287
[TBL] [Abstract][Full Text] [Related]
34. Population pharmacokinetics and dosage optimisation of tacrolimus coadministration with Wuzhi capsule in adult liver transplant patients.
Du Y; Song W; Xiong X; Ge W; Zhu H
Xenobiotica; 2022 Mar; 52(3):274-283. PubMed ID: 35502774
[TBL] [Abstract][Full Text] [Related]
35. Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients.
Benkali K; Prémaud A; Picard N; Rérolle JP; Toupance O; Hoizey G; Turcant A; Villemain F; Le Meur Y; Marquet P; Rousseau A
Clin Pharmacokinet; 2009; 48(12):805-16. PubMed ID: 19902988
[TBL] [Abstract][Full Text] [Related]
36. The influence of recipient SLCO1B1 rs2291075 polymorphism on tacrolimus dose-corrected trough concentration in the early period after liver transplantation.
Wu Y; Fang F; Wang Z; Wen P; Fan J
Eur J Clin Pharmacol; 2021 Jun; 77(6):859-867. PubMed ID: 33386894
[TBL] [Abstract][Full Text] [Related]
37. Importance of hematocrit for a tacrolimus target concentration strategy.
Størset E; Holford N; Midtvedt K; Bremer S; Bergan S; Åsberg A
Eur J Clin Pharmacol; 2014 Jan; 70(1):65-77. PubMed ID: 24071959
[TBL] [Abstract][Full Text] [Related]
38. Population pharmacokinetic study of tacrolimus in pediatric patients with primary nephrotic syndrome: A comparison of linear and nonlinear Michaelis-Menten pharmacokinetic model.
Huang L; Liu Y; Jiao Z; Wang J; Fang L; Mao J
Eur J Pharm Sci; 2020 Feb; 143():105199. PubMed ID: 31862313
[TBL] [Abstract][Full Text] [Related]
39. Tacrolimus population pharmacokinetics according to CYP3A5 genotype and clinical factors in Chinese adult kidney transplant recipients.
Zhang HJ; Li DY; Zhu HJ; Fang Y; Liu TS
J Clin Pharm Ther; 2017 Aug; 42(4):425-432. PubMed ID: 28401703
[TBL] [Abstract][Full Text] [Related]
40. Effect of drug combination on tacrolimus target dose in renal transplant patients with different
Zhang SF; Tang BH; Wei AH; Du Y; Guan ZW; Li Y
Xenobiotica; 2022 Mar; 52(3):312-321. PubMed ID: 35395919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
